RenovoRxRNXT
Recorded

RenovoRx Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum

Review the key takeaways and the transcript of this earnings call.

Period 0Duration20 minParticipants3

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Jon YoungDirector of Wealth Management

Great. Good afternoon, everyone, and thank you for joining us. My name is John Young, and I am a MedTech research analyst here at Canaccord Genuity. Welcome to our MedTech, Diagnostics, Digital Health, and Services Forum. I am very pleased to introduce our next presenter, Shaun Bagai, Chief Executive Officer of RenovoRx, and Mark Voll, CFO. For those less familiar with the story, RenovoRx is a commercial-stage company that sells the RenovoCath, an FDA-cleared dual-balloon catheter that delivers chemotherapy locally across the arterial wall near the tumor, and is running a phase III trial of its drug-device combination in locally advanced pancreatic cancer. Shaun, thanks for being here.

Shaun BagaiCEO

Thank you for the introduction. Thank you for everyone joining here in person and online as well. Shaun Bagai here, CEO of RenovoRx, and I wanted to give you an update on where we have come with our new TAMP technology, both commercially and clinically. Just a very high level, we have been looking at cancers very differently than most companies. If you think about new therapeutics, it is a fine balance between destroying the patient and destroying the tumor. What we are after is, how do we actually treat cancer in a manner that does not destroy the entire body while you are trying to tackle the tumor itself? With that very high level, we have got an FDA-cleared device called the RenovoCath. Currently, we are in 26 active customers around the country, and we are accelerating market penetration with a small, lean sales force that is now fully active.

Shaun BagaiCEO

The estimated annual target revenue for the device alone product is estimated to be at $400 million per year. In parallel, we are developing a proprietary technology via our TAMP mechanism, otherwise known as Trans-Arterial Micro-Perfusion, in a phase III trial right now called TIGeR-PaC that is fully enrolled. This TIGeR-PaC trial is specifically looking at the combination therapy of gemcitabine through our RenovoCath device, and I will give you more detail after that in a minute here. From a leadership team perspective, I will walk through that towards the end. We have got the right team in place, both on the clinical development side, on the commercial side, and spanning biotech and medical devices. Let us step back and first talk about the issue we are trying to tackle, and one of the biggest unmet needs and the issue with therapy today in specific tumors like pancreatic cancer tumors.

Shaun BagaiCEO

When you think about solid tumors, you usually think about balls of blood vessels with tumor cells. This poses a great entry point for chemotherapy to reach tumors. On the panel on the left, what you are seeing there is an animation of what looks like a liver tumor. You can see a blood vessel that feeds that liver tumor and ends directly in the tumor. This serves as a vascular highway, if you will, where chemotherapy can circulate the body, but also reach the tumor itself, and it also provides a target for physicians to place a small microcatheter or plastic tube inside the liver tumor feeder. Unfortunately, many tumors in the bodies do not have these types of tumor feeders. If you look at pancreatic cancers, glioblastoma, cholangiocarcinoma, certain non-small cell lung cancers, they do not have a large direct connection to the blood supply.

Shaun BagaiCEO

The tumors grow very slowly, they die on the inside as they grow, and they get very little nutrients from the body. This poses really a resistance or a barrier of success of chemotherapy and standard therapies today. These are considered hypovascular tumors, not having large blood supplies. The whole crux of our system is to overcome this challenge to successful therapy. Our mechanism is called TAMP, or Trans-Arterial Micro-Perfusion, and the way this works is a physician places our proprietary RenovoCath device under X-ray fluoroscopic guidance. This is done by an interventional radiologist.

Shaun BagaiCEO

They place the catheter adjacent to the tumor, and then using the proprietary nature, change the distance between the balloons to isolate blood flow specifically to a small part of the artery or blood vessel without any side branches or vessels that are leading away from the tumor between the balloons, where the chemotherapy can drain away and wash away. By that isolation, they give a full systemic dose and volume of chemotherapy over 20 minutes. Imagine a liter of fluid, and that small space is about one or two milliliters in volume over 20 minutes. That creates a pressure head that forces the therapy across the vessel wall and the tissue. What this results in is a very high concentration of the drug or the therapy at the tissue or tumor site, versus just washing away systemically. We do this using pressure.

Shaun BagaiCEO

Once the pressure starts to increase when that small space fills up, it doesn't get to very high dangerous pressures, but enough to push the drug through the vessel wall into the tissue. The result is, what you see in an animal study is about 100 times the concentration of the dose. You can imagine what effect we can have on the tumor cells with a much higher dose at the tumor site. On the flip side, what we're seeing is a much less systemic volume, which makes sense because we're not exposing the entire body to the drug. It's starting at the tissue side of the tumor. The panel on the left was actually a proof of concept in lung tissue, to see if we can use this in lung cancers in the animal model.

Shaun BagaiCEO

The panel on the right is actually human data from our phase III TIGeR-PaC study. We did a subset PK analysis. This paper was just published within the last couple of months, showing almost a 50% reduction in systemic chemotherapy when delivered locally via our TAMP mechanism, versus giving it systemically. What this translates into patients from a procedural standpoint is that patients come in every other week. It's usually a treatment course of up to eight treatments over four months. Compared to other new technologies, it's not an overnight stay in the hospital. Generally, these patients are outpatients, and they're given just local anesthesia to feel comfortable. They don't have to be put under general anesthesia for the most case. From a patient expectation and a patient experience, it's not difficult.

Shaun BagaiCEO

In fact, they prefer this mechanism to standard of care because they don't see the chemotherapy side effects. It is an outpatient procedure. From a physician standpoint, it's the same exact skill sets they use to treat local liver tumors. It's just a matter of having a proctor there for two to three procedures, and then the physicians are free to go on their own or train other doctors. We don't need a big field force to train and drive the adoption of the technology because it's relatively simple to use for the physicians as well. So far, we've seen usage to date in locally advanced pancreatic cancer. We have the most data. As far as what's coming next, the market itself for pancreatic cancer is about 60,000 patients per year. We've been focusing in our clinical trials on locally advanced pancreatic cancer.

Shaun BagaiCEO

That's considered non-resectable, not yet metastatic. You look at the entire market, we're talking about $1 billion of TAM or several billion dollars of TAM. Next, we're looking at cholangiocarcinoma or a bile duct cancer. There's been interest from physicians looking at, okay, where can this be used outside of pancreatic cancer given the success we've seen? Biliary tumors or bile duct cancers are one that behave like pancreatic tumors. They don't have large blood supplies, and the same drugs are being used. Beyond that, there's a lot of potential. We look at this as a platform play, as we can deliver almost any agent to almost any tumor. The tumors that make the most sense to physicians on next steps are going upstream and downstream of locally advanced pancreatic cancer. In fact, we've already launched an IIT, an investigator-initiated trial, in borderline pancreatic cancer.

Shaun BagaiCEO

That's patients who are slated to go for surgery, but not yet resectable. Metastatic pancreatic cancer is a larger part of the market, and we have an IIT about to launch in metastatic pancreatic cancer as well. Beyond that, we have treated our first sarcoma patient, which we announced a few months ago. Physicians, as they're adopting this FDA-cleared technology, are finding other uses where this could be beneficial to the patient population. Longer-term non-small cell lung cancer, glioblastoma, pelvic tumors, and other indications are on the horizon as well. It gives us a lot of optionality in terms of where this could be used as a platform. As newer drugs are developed and come out, we can actually put those through our device. It gives us a leg up on really having no competition.

Shaun BagaiCEO

We've developed and invented a new mechanism of action on driving high doses of chemotherapy in the tumors. With that, I'll have Mark talk about the commercial opportunity of the device we have today.

Mark VollCFO

If we look at the market opportunity for our product, I will take you through how we view the market itself. Our device sells for $8,000-$8,500 per device. Typically, a patient will go through 5-10 procedures. We see an annual revenue opportunity for us of approximately $400 million. Not only is it a significant market opportunity, but it is a high-margin business. Currently, our product drives a gross margin of 85%. Our next-generation product we will introduce sometime next year. We believe that we can even improve on that. It is really a low-overhead model. We only require five field sales representatives to sell our product. As a result, we see a very high-margin operating margin business, and we think that longer-term, we can generate 30% in operating margins for the business.

Mark VollCFO

Also, we have a robust patent portfolio, which we think provides a significant defensible barrier for our product. Why would we think that there is a low overhead business? We believe that we currently have five salespeople in place. We believe that is sufficient to cover the total market. There is approximately 200 hospitals that treat most all of the pancreatic cancers in the U.S. It is really a concentrated market. The top 25 generate over 40% of the diagnosis in the United States on an annual basis, and even the top 100 represent more than three-quarters of the total market. We think that, again, our sales force that we have in place is sufficient to drive revenue for our company.

Mark VollCFO

We have been quite successful the first three quarters of this year, generating last quarter $1.1 million in revenue, our first quarter in which we generated more than $1 million in revenue. We have generated $2.5 million for the first three quarters, and we think now that our sales force is in place and their experience on the product will be able to generate future growth that will surpass our current growth.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day